SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending amid community excitement and discussion around a potential token burn as it approaches a watcher milestone. The community is expressing strong conviction and encouraging others to "load up" during a perceived dip, highlighting the project's resilience and long-term vision within the Solana meme coin space. There is also discussion about an upcoming listing on Bifinance.

Terner is an AI-powered platform on Solana that enables users to create, deploy, and crowdfund innovative projects through natural language interaction. The platform combines advanced AI capabilities with blockchain technology to democratize project creation, offering tools for building web applications, bots, and various digital solutions while providing automated deployment and investment opportunities for creators and investors alike.

Terner

TERNER.X is gaining attention as a new AI and blockchain project on the Solana network, with the community highlighting its potential for building web applications and bots. Many users are sharing links to purchase the token on Phantom Wallet and expressing excitement about its long-term prospects. The conversation includes speculation on the project's roadmap and potential for high returns.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is surging amidst renewed interest in the quantum computing sector, potentially fueled by government initiatives and the company's presence at a recent conference. Community discussions revolve around whether the stock's momentum is sustainable and if it will continue outpacing its peers, as well as speculation regarding potential acquisitions. Investors are also closely monitoring for news from the company that could further drive the stock's price.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to significant price momentum, with the community discussing potential government support and AI applications driving speculation. Some traders are pointing to a possible short squeeze, while others caution about the company's lack of current revenue and potential insider selling. Overall, the community's sentiment is mixed, acknowledging both the potential and the risks associated with the stock.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is trending as the community discusses its potential, particularly its integration with the X platform via the BANKR BOT and new listing on Coinbase. Some are excited about its AI utility and connection to the Base ecosystem, while others are watching key resistance levels and anticipating a breakout. The broader discussion includes speculation on potential Binance listing and the impact of macro factors like possible Fed rate cuts.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to a recently announced $53 million AI server contract, sparking excitement among investors. The community is actively discussing the potential for a short squeeze, given the stock's low float and high cost to borrow, while also acknowledging the company's history of reverse splits.

Sogent

Sogent is trending as community members highlight its availability on Phantom Wallet, fueling speculation about a potential price surge. The token is being discussed alongside broader interest in the Solana ecosystem, with some users expressing bullish sentiment.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE.X is trending as the community expresses enthusiasm and memes about the token. Conversations mention potential partnerships with UPDOG.X and general bullish sentiment with some users stating 'wen lambo' and 'to the moon'.

Owens & Minor, Inc. is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments. The Products and Healthcare Services segment includes medical distribution, the outsourced logistics and value-added services business, and global products, which manufacture and source medical surgical products through the production and kitting operations. The Patient Direct segment includes the home healthcare business, Byram and Apria. The company was founded by Otho O. Owens and G. Gilmer Minor in 1882 and is headquartered in Henrico County, VA.

Owens & Minor, Inc.

Owens & Minor is experiencing notable trading activity, with community members pointing to its removal from the S&P SmallCap 600 as a catalyst for recent high volume due to forced selling by index funds. Despite longer-term fundamental concerns, some traders anticipate a short-term relief bounce following this index deletion flush, while others highlight potential institutional buying as a bullish signal. Active discussion revolves around whether the stock's reaction to high selling volume indicates underlying strength and a potential upcoming move higher.

The first liquid staking derivative on Solana to include MEV rewards. Tracks the price of SOL while accruing staking and MEV rewards. Yield is accrued in the price so it will steadily appreciate vs. SOL.

Jito Staked SOL

Jito Staked SOL ($JITOSOL.X) is trending amid discussions about liquid staking and its benefits, particularly following news that the SEC isn't classifying certain liquid staking activities as securities transactions. The community is highlighting the ability to earn APR and MEV rewards, as well as the utility of liquid tokens in DeFi. Recent listings on exchanges like Bullish, Gemini, and OKX are also contributing to the increased interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.

Agios Pharmaceuticals, Inc. (AGIO) announced on Thursday that the U.S. Food and Drug Administration has extended the review period for its drug Pyrukynd, intended for the treatment of adult patients with thalassemia, by three months.Thalassemia is a rare, inherited blood disease that affects the production of the protein hemoglobin in red blood cells. By disrupting hemoglobin production, thalassemia reduces the number of circulating red blood cells and shortens their lifespan, resulting in anemia, fatigue, and severe complications.While the FDA was initially expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.agios.com/news-releases/news-release-details/agios-provides-update-us-pdufa-goal-date-pyrukyndr-mitapivat">expected</a> by December 7. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AGIO">AGIO stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:585/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_10_30_42_AM_png_307a186918.webp" alt="AGIO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="585" height="62"><figcaption>AGIO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that these are circumstances beyond the company's control.<stembedurl>https://stocktwits.com/forprofit12/message/627455227</stembedurl>A pessimistic user, however, called for selling the company's shares.<stembedurl>https://stocktwits.com/Jadek6/message/627455837</stembedurl>In the original application, the company had described the risk of hepatocellular injury with the drug. However, the firm stated on Thursday that it has submitted a proposed Risk Evaluation and Mitigation Strategy (REMS) in response to a recent information request from the agency.The extension in date of the FDA’s decision is not the result of new or additional efficacy or safety data requested by the FDA or submitted by Agios, but a result of the new REMS submission, the company said. It further termed the REMS submission a major amendment to its original application.“We remain confident in the favorable benefit-risk profile of PYRUKYND in thalassemia,” said CEO Brian Goff. &nbsp;As per Agios, approximately 6,000 adult patients are diagnosed with thalassemia in the U.S.BofA subsequently lowered its price target on Agios Pharmaceuticals to $51 from $52 while keeping a ‘Buy’ rating on the shares. The firm noted that the extension was not the result of new data requested by the FDA or submitted by the company. BofA still views approval in thalassemia as likely given its key opinion leader checks and the strength of data from late-stage trials supporting the application. As such, Agios remains one of the firm's top picks even with the delay, it said.Pyrukynd is already approved for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. Pyruvate kinase (PK) deficiency is a rare, inherited disorder causing chronic hemolytic anemia in adults, where red blood cells break down too quickly due to a lack of the PK enzyme, resulting in low red blood cell count.AGIO stock is up by 6% this year but down by over 22% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/fda-says-no-advisory-commitee-meeting-required-for-aquestive-oral-epinephrine-film/chwd20pRdYB">FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More 

While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7. 

Equity

Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Retail chatter around Agios Pharmaceuticals spiked Tuesday after the company said that Saudi Arabia’s Food and Drug Authority (SFDA) approved Pyrukynd (mitapivat) for the treatment of adult patients with alpha- or beta-thalassemia, regardless of transfusion status.The approval was granted under the SFDA’s Breakthrough Medicines Program and is based on results from the global Energize and Energize-T Phase 3 trials.&nbsp;<a href="https://stocktwits.com/symbol/AGIO">Shares of Agios Pharmaceuticals</a> closed 3.3% higher at $36.16 on Monday, with the stock rising another 2% in after-hours trading to $36.88.Agios had partnered with NewBridge Pharmaceuticals in 2024 to support regional commercialization efforts across the Gulf Cooperation Council (GCC), including the UAE, Kuwait, Qatar, Oman, and Bahrain.However, the milestone approval came alongside new safety scrutiny in the U.S. market.&nbsp;Leerink analyst Andrew Berens noted that three newly listed deaths involving Pyrukynd appeared in the FDA’s Adverse Event Reporting System (FAERS) in July, bringing the total to four since launch.Two of the July cases were in young patients. Berens called the developments “potentially concerning” but cautioned that FAERS entries often lack key details and context.In a regulatory filing, Agios said it was aware of the report and confirmed that three of the four cases had already been submitted to the FDA through standard pharmacovigilance processes.&nbsp;Two patients involved&nbsp;were treated with Pyrukynd for pyruvate kinase deficiency under its approved U.S. indication, while one patient with sickle cell disease&nbsp;was treated through expanded access.&nbsp;The fourth case had been reported directly to the FDA, and Agios said it is currently evaluating it.The company added that, to date, the available information does not change Pyrukynd’s benefit-risk profile as represented in its U.S. prescribing information.A regulatory decision on Pyrukynd for thalassemia is due from the U.S. FDA by Sept. 7. Additional filings are under review in the UAE and European Union.On Stocktwits, retail sentiment for Agios was ‘bullish’ amid ‘extremely high’ message volume.One user acknowledged not being bullish on the stock but noted that each reported death involved patients with severe underlying conditions.&nbsp;“Two were dealing with sickle cell complications, one was 93 and already critically ill — none were stable patients simply adding Pyrukynd to an existing regimen,” the user wrote, suggesting the outcomes may not reflect typical treatment scenarios.&nbsp;<stembedurl>https://stocktwits.com/Dkll303/message/623704770</stembedurl>Another user focused on the day’s sharp intraday recovery, and said the stock had an “absolutely incredible recovery.”<stembedurl>https://stocktwits.com/yachtsandthots/message/623705222</stembedurl>Agios’ stock has risen 13.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter around Agios Pharmaceuticals (AGIO) spiked Tuesday after the company said that Saudi Arabia’s Food and Drug Authority (SFDA) approved Pyrukynd. (Photo credit: Getty Images)

Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns

Retail investors defended Agios on Stocktwits, saying reported deaths involved critically ill patients and didn’t reflect typical use. 

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?

Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?

Earnings Preview: Agios Pharmaceuticals

4 Analysts Have This To Say About Agios Pharmaceuticals

Latest Ratings for AGIO
 DateFirmActionFromTo Mar 2022Goldman SachsMaintainsSell Mar 2022HC Wainwright & Co.MaintainsBuy Feb 2022RBC CapitalMaintainsOutperform
 View More Analyst Ratings for...

Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.
read more...

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

AGIO
Agios Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AGIO News

AGIO Agios Pharmaceuticals Inc